The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
February 24, 2017
Wrong Site/Patient/Procedure Surgeries: Solutions for Prevention The Florida Board of Medicine has been holding meetings and conducting research on incidents of wrong site/person/procedure surgeries in Florida. While the overall number of incidents (when compared to the number of surgeries performed) … Continue reading
January 19, 2017
Please see updated information about the DEA’s suspension of McKesson Corporation and controlled substances Continue reading